Ori Gutwerg Biography and Net Worth

Senior Vice President, Generics of ANI Pharmaceuticals

Mr. Gutwerg is a seasoned leader and brings more than 17 years of experience building and driving growth in pharmaceutical companies. Most recently, Mr. Gutwerg served as Vice President, Head of U.S. Generics Rx at Taro Pharmaceuticals, overseeing a portfolio of nearly 300 generic and branded products. In that role, he drove double-digit top- and bottom-line growth, improved working capital through cost savings and efficiencies, rationalized the R&D pipeline and negotiated numerous business development deals to accelerate growth. Prior to joining Taro, he held positions with Xiromed US, Perrigo Pharmaceuticals, and Agis Group. Throughout his career, he has managed sales teams, built a commercial operations team, led M&A due diligence activities, and negotiated new business development and joint venture agreements. Mr. Gutwerg has a B.S. in Communications and Economics from The College of Management and an M.B.A. from Tel Aviv University.

What is Ori Gutwerg's net worth?: The estimated net worth of Ori Gutwerg is at least $5.39 million as of May 15th, 2025. Mr. Gutwerg owns 89,897 shares of ANI Pharmaceuticals stock worth more than $5,392,921 as of May 19th. This net worth evaluation does not reflect any other assets that Mr. Gutwerg may own. Additionally, Mr. Gutwerg receives an annual salary of $895,160.00 as Senior Vice President, Generics at ANI Pharmaceuticals. Learn More about Ori Gutwerg's net worth.
How old is Ori Gutwerg?: Mr. Gutwerg is currently 49 years old. There are 7 older executives and no younger executives at ANI Pharmaceuticals. The oldest executive at ANI Pharmaceuticals is Mr. James G. Marken, Senior Vice President of Operations, who is 61 years old. Learn More on Ori Gutwerg's age.
What is Ori Gutwerg's salary?: As the Senior Vice President, Generics of ANI Pharmaceuticals, Inc., Mr. Gutwerg earns $895,160.00 per year. There are 2 executives that earn more than Mr. Gutwerg. The highest earning executive at ANI Pharmaceuticals is Mr. Nikhil Lalwani, President, CEO & Director, who commands a salary of $2,320,000.00 per year. Learn More on Ori Gutwerg's salary.
How do I contact Ori Gutwerg?: The corporate mailing address for Mr. Gutwerg and other ANI Pharmaceuticals executives is 210 Main Street West, Baudette MN, 56623. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at [email protected]. Learn More on Ori Gutwerg's contact information.
Has Ori Gutwerg been buying or selling shares of ANI Pharmaceuticals?: Within the last three months, Ori Gutwerg has sold $52,921.67 of ANI Pharmaceuticals stock. Most recently, Ori Gutwerg sold 881 shares of the business's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.07, for a transaction totalling $52,921.67. Following the completion of the sale, the senior vice president now directly owns 89,897 shares of the company's stock, valued at $5,400,112.79. Learn More on Ori Gutwerg's trading history.
Who are ANI Pharmaceuticals' active insiders?: ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Stephen Carey (Senior Vice President, Finance and Chief Financial Officer), Meredith Cook (Senior Vice President, General Counsel and Corporate Secretary), Krista Davis (Senior Vice President and Chief Human Resources Officer), Chad Gassert (Senior Vice President, Corporate Development and Strategy), Ori Gutwerg (Senior Vice President, Generics), Thomas Haughey (Director), Nikhil Lalwani (Pres), Nikhil Lalwani (President and Chief Executive Officer), James Marken (Senior Vice President, Operations and Product Development), Christopher Mutz (Insider), Antonio Pera (Director), Muthusamy Shanmugam (Head of R&D and COO of NJ Operations), Muthusamy Shanmugam (Head of R&D and COO), Renee Tannenbaum (Director), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ANI Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 25 times. They sold a total of 159,809 shares worth more than $9,777,989.53. The most recent insider tranaction occured on May, 15th when SVP Ori Gutwerg sold 881 shares worth more than $52,921.67. Insiders at ANI Pharmaceuticals own 11.1% of the company. Learn More about insider trades at ANI Pharmaceuticals.
Information on this page was last updated on 5/15/2025.

Ori Gutwerg Insider Trading History at ANI Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2025	Sell	881	$60.07	$52,921.67	89,897
6/5/2024	Sell	2,985	$67.00	$199,995.00	77,227
8/23/2023	Sell	15,561	$62.39	$970,850.79	60,915

Ori Gutwerg Buying and Selling Activity at ANI Pharmaceuticals

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Today's Range

Now: $60.16

$58.94

$60.20

50 Day Range

MA: $66.91

$59.53

$72.95

2 Week Range

Now: $60.16

$52.50

$77.00

Volume

268,194 shs

Average Volume

298,783 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Ori Gutwerg Biography and Net Worth

What is Ori Gutwerg's net worth?

How old is Ori Gutwerg?

What is Ori Gutwerg's salary?

How do I contact Ori Gutwerg?

Has Ori Gutwerg been buying or selling shares of ANI Pharmaceuticals?

Who are ANI Pharmaceuticals' active insiders?

Are insiders buying or selling shares of ANI Pharmaceuticals?